Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | ROR1 | Q01973 | 7/20 | 0.37 |
| ▸ | ABL1 | P00519 | 4/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16704334 | 0.74 | MKNK1 (0.46) | MKNK1CSF1RROR1ABL1KLK7 | |
| SCHEMBL588504 | 0.72 | MKNK1 (0.44) | MKNK1CSF1RROR1ABL1KLK7 | |
| SCHEMBL22369939 | 0.71 | MKNK1 (0.46) | MKNK1CSF1RROR1ABL1KLK7 | |
| SCHEMBL22580709 | 0.70 | CSF1R (0.61) | CSF1RROR1ABL1 | |
| SCHEMBL10207631 | 0.69 | MKNK1 (0.44) | MKNK1CSF1RROR1ABL1DYRK1A | |
| SCHEMBL29890013 | 0.69 | MKNK1 (0.41) | MKNK1CSF1RROR1ABL1KLK7 | |
| SCHEMBL24496139 | 0.68 | MKNK1 (0.43) | MKNK1CSF1RROR1ABL1KLK7 | |
| SCHEMBL19840388 | 0.68 | MKNK1 (0.49) | MKNK1KLK7DYRK1A | |
| SCHEMBL17471717 | 0.66 | CSF1R (0.57) | CSF1RROR1ABL1 | |
| SCHEMBL15096062 | 0.65 | ROR1 (0.67) | CSF1RROR1ABL1DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018089736-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | WO | disclosed |